These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1125562)

  • 21. Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses.
    Gip L; Hamfelt A
    Cutis; 1984 Feb; 33(2):215-7, 220-2, 224. PubMed ID: 6365474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of iatrogenic Cushing syndrome: questions of glucocorticoid withdrawal].
    Igaz P; Rácz K; Tóth M; Gláz E; Tulassay Z
    Orv Hetil; 2007 Feb; 148(5):195-202. PubMed ID: 17344139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate.
    Malik KJ; Wakelin K; Dean S; Cove DH; Wood PJ
    Ann Clin Biochem; 1996 May; 33 ( Pt 3)():187-9. PubMed ID: 8791979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generalized pustular psoriasis on withdrawal of clobetasol propionate ointment.
    Boxley JD; Dawber RP; Summerly R
    Br Med J; 1975 May; 2(5965):255-6. PubMed ID: 1131576
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect on adrenal function of topically applied clobetasol propionate (Dermovate).
    Allenby CF; Main RA; Marsden RA; Sparkes CG
    Br Med J; 1975 Dec; 4(5997):619-21. PubMed ID: 1203701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatal iatrogenic Cushing's syndrome.
    Nathan AW; Rose GL
    Lancet; 1979 Jan; 1(8109):207. PubMed ID: 84219
    [No Abstract]   [Full Text] [Related]  

  • 27. The safety of halobetasol 0.05% ointment in the treatment of psoriasis.
    Watson WA; Kalb RE; Siskin SB; Freer JP; Krochmal L
    Pharmacotherapy; 1990; 10(2):107-11. PubMed ID: 2349135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic value of hypothalamic-pituitary-adrenocortical function tests in patients with Cushing's syndrome.
    Hashimoto K
    Acta Med Okayama; 1975 Apr; 29(2):111-26. PubMed ID: 169671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observations on the systemic effect of topical clobetasol propionate (Dermovate).
    Carruthers JA; August PJ; Staughton RC
    Br Med J; 1975 Oct; 4(5990):203-4. PubMed ID: 1191997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Betamethasone valerate in corticosteroid-dependent asthmatics. The integrity of the hypothalamic pituitary adrenal axis.
    Roscoe P; Choo-Kang YF; Horne NW
    Br J Dis Chest; 1975 Oct; 69(0):240-6. PubMed ID: 1106745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cushing's syndrome caused by topical steroid therapy for psoriasis.
    Abma EM; Blanken R; De Heide LJ
    Neth J Med; 2002 Apr; 60(3):148-50. PubMed ID: 12164372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of betamethasone 17-propionate and betamethasone on hypothalamo-pituitary-adrenal cortex axis in rats (author's transl)].
    Nakano M; Takeuchi M; Sugeno K
    Nihon Yakurigaku Zasshi; 1980 Nov; 76(8):729-35. PubMed ID: 7274840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iatrogenic Cushing's syndrome and topical steroid therapy: case series and review of the literature.
    Decani S; Federighi V; Baruzzi E; Sardella A; Lodi G
    J Dermatolog Treat; 2014 Dec; 25(6):495-500. PubMed ID: 23210698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Double-blind-study on treatment with clobetasol-17-propionate and other topical corticoids (author's transl)].
    Beck M; Berger C; Filipp N; Hundertmark U; Loewel R
    Z Hautkr; 1981 Aug; 56(16):1066-70. PubMed ID: 7027655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
    Sofen H; Hudson CP; Cook-Bolden FE; Preston N; Colón LE; Colón LE; Caveney SW; Gottschalk RW
    J Drugs Dermatol; 2011 Aug; 10(8):885-92. PubMed ID: 21818510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iatrogenic Cushing's syndrome--a cautionary tale.
    Lawlor F; Ramabala K
    Clin Exp Dermatol; 1984 May; 9(3):286-9. PubMed ID: 6329563
    [No Abstract]   [Full Text] [Related]  

  • 37. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
    Jorizzo JL; Magee K; Stewart DM; Lebwohl MG; Rajagopalan R; Brown JJ
    Cutis; 1997 Jul; 60(1):55-60. PubMed ID: 9252738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apparently normal pituitary-adrenal suppressibility in Cushing's syndrome: dexamethasone metabolism and plasma levels.
    Meikle AW; Lagerquist LG; Tyler FH
    J Lab Clin Med; 1975 Sep; 86(3):472-8. PubMed ID: 1151162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is suppression of hypothalamic-pituitary-adrenal axis significant during clinical treatment of phimosis?
    Pileggi FO; Martinelli CE; Tazima MF; Daneluzzi JC; Vicente YA
    J Urol; 2010 Jun; 183(6):2327-31. PubMed ID: 20400146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
    Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.